sorafenib has been researched along with regorafenib in 129 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (regorafenib) | Trials (regorafenib) | Recent Studies (post-2010) (regorafenib) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 884 | 122 | 857 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 76 (58.91) | 24.3611 |
| 2020's | 53 (41.09) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, SH; Hammock, BD; Hwang, SH; Morisseau, C; Nguyen, LV; Wecksler, AT; Zhang, G | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Bestgen, B; Borjini, N; Chevé, G; Daydé-Cazals, B; Fauvel, B; Feneyrolles, C; Gassiot, F; Singer, M; Spenlinhauer, A; Van Hijfte, N; Warnault, P; Yasri, A | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Abou-Zeid, LA; El-Mesery, M; El-Sayed, MA; Gomaa, RM; Mostafa, AS; Selim, KB; Zeidan, MA | 1 |
| Abdel-Mohsen, HT; Ali, MM; El Diwani, HI; El Kerdawy, AM; Mahmoud, AEE; Omar, MA | 1 |
| Bharate, SB; Raghuvanshi, R | 1 |
| Acharya, B; Frett, B; Garcia, NG; Lakkaniga, NR; Ryan, KR; Saha, D; Smith, EL | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Carr, BI; Cavallini, A; Correale, M; D'Alessandro, R; Di Carlo, A; Iacovazzi, PA; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Al-Marrawi, MY; Brennan, MC; Dykes, TM; El-Deiry, WS; Saroya, BS; Yang, Z | 1 |
| Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
| Gao, B; Lu, M; Qiao, X; Wang, X; Xue, D; Zhang, Y | 1 |
| Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Fujiya, T; Hasegawa, Y; Kakugawa, Y; Kinouchi, M; Miura, K; Philchenkov, A; Satoh, M; Yamamoto, K | 1 |
| Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
| Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M | 1 |
| Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 1 |
| Burns, K; Knights, KM; Mackenzie, PI; Miners, JO; Nair, PC; Rowland, A | 1 |
| Carr, BI; D'Alessandro, R; Messa, C; Refolo, MG | 1 |
| Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
| Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M | 1 |
| Tan, S; Tong, J; Yu, J; Zhang, L; Zou, F | 1 |
| Chen, KF; Fan, LC; Hung, MH; Jiang, JK; Shiau, CW; Tai, WT; Teng, HW; Yang, SH | 1 |
| Abel, T; Haralampiev, I; Herrmann, A; Huster, D; Luckner, M; Müller, P; Scheidt, HA | 1 |
| Bruix, J; Reig, M; Ribeiro de Souza, A | 1 |
| Baumhauer, A; Bodoky, G; Breder, V; Bronowicki, JP; Bruix, J; Cheng, AL; Finn, RS; Gerolami, R; Granito, A; Han, G; Huang, YH; Kudo, M; LeBerre, MA; Llovet, JM; Masi, G; Meinhardt, G; Merle, P; Ollivier-Hourmand, I; Pracht, M; Qin, S; Rosmorduc, O; Ross, PJ; Song, T; Yokosuka, O | 1 |
| Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
| Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
| Angenstein, F; Baldauf, L; Daniel, EA; Kirches, E; Mawrin, C; Pachow, D; Scholz, J; Stork, O; Tuchen, M; Wilisch-Neumann, A | 1 |
| Galle, PR; Wörns, MA | 2 |
| Allard, M; Blanchet, B; Costentin, C; Hulin, A; Joly, C; Khoudour, N; Rousseau, B; Tournigand, C | 1 |
| Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P | 1 |
| Casadei Gardini, A; Ercolani, G; Foschi, FG; Frassineti, GL; Ulivi, P | 1 |
| Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A | 1 |
| Personeni, N; Pressiani, T; Rimassa, L; Santoro, A | 1 |
| Barbera, MA; Biasco, G; Brandi, G; Frega, G; Garajova, I; Lorenzo, S; Palloni, A; Pantaleo, MA; Tovoli, F | 1 |
| Karasic, TB; O'Dwyer, PJ; Rosen, MA | 1 |
| Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
| Arai, M; Chiba, T; Inoue, M; Kanda, T; Kato, N; Kiyono, S; Kobayashi, K; Maeda, T; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Wakamatsu, T; Yasui, S; Yokosuka, O; Yokoyama, M | 1 |
| El-Serag, HB; Johnson, MS; Zhu, AX | 1 |
| Kudo, M; Nishida, N; Ueshima, K | 1 |
| Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H | 1 |
| Abou-Alfa, GK; Dika, IE | 1 |
| Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F | 1 |
| Bi, Y; Casak, S; Goldberg, KB; Jiang, X; Keegan, P; Lemery, S; Liu, J; McKee, AE; Patel, A; Pazdur, R; Pelosof, L; Pierre, V; Rodriguez, L; Zirkelbach, JF | 1 |
| Bolondi, L; De Lorenzo, S; Granito, A; Tovoli, F | 1 |
| Baumhauer, A; Bodoky, G; Bruix, J; Cabrera, R; Caparello, C; Chang, C; Finn, RS; Gerolami, R; Granito, A; Huang, YH; LeBerre, MA; Meinhardt, G; Merle, P; Pracht, M; Rosmorduc, O; Sun, W; Yokosuka, O | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I | 1 |
| Chai, S; Che, N; Ding, J; Kau, PW; Lee, TK; Lo, CM; Luk, ST; Ma, S; Man, K; Ngan, ES; Tong, M; Zhou, L | 1 |
| Heo, YA; Syed, YY | 1 |
| Álvares-da-Silva, MR; de Freitas, LBR; Grivicich, I; Longo, L; Santos, D | 1 |
| Peck-Radosavljevic, M; Pinter, M | 1 |
| Finn, RS; Llovet, JM; Montal, R; Sia, D | 1 |
| Abdel-Rahman, O; Cheung, WY | 1 |
| Canbay, A; Franck, C; Franke, S; Haybaeck, J; Rosania, R; Venerito, M | 1 |
| He, XX; Li, QT; Qiu, MJ; Shi, LL; Wang, MM; Xiong, ZF; Yang, SL | 1 |
| Annicchiarico, BE; Cerrito, L; Garcovich, M; Gasbarrini, A; Pompili, M; Ponziani, FR; Siciliano, M; Tortora, A | 1 |
| Abe, M; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, Y; Joko, K; Koizumi, Y; Michitaka, K; Ochi, H; Watanabe, T; Yoshida, O; Yukimoto, A | 1 |
| Goldstein, DA; Leshno, M; Shlomai, A | 1 |
| Chen, H; Li, J; Liu, C; Pui, Y; Qian, F; Wang, S; Xu, CQ; Yu, J; Zhu, AD | 1 |
| Kim, DY; Kim, YJ; Lee, SJ; Lim, HY; Lim, TS; Park, JW; Ryoo, BY; Yoo, C; Yu, SJ | 1 |
| Cai, H; Chen, W; Chen, X; Sun, D; Yang, J; Zhang, Y | 1 |
| Barclay, W; Frise, R; Gravenstein, I; Herrmann, A; Imai-Matsushima, A; Karlas, A; Lesch, M; Luckner, M; Martin-Sancho, L; Meyer, M; Meyer, TF; Raftery, M; Schönrich, G; Sieben, C; Weege, F; Welke, RW | 1 |
| Du, Y; Liang, Q; Liu, S; Ma, H; Tian, J; Zhu, X | 1 |
| Bouattour, M; Hulin, A; Stocco, J | 1 |
| Chen, H; Chen, Y; Liu, C; Qian, F; Wang, S | 1 |
| Abo-Ali, EM; Barot, S; Dukhande, VV; Palaguachi, C; Zhou, DL | 1 |
| Arai, M; Atsukawa, M; Azemoto, R; Chiba, T; Haga, Y; Inoue, M; Itobayashi, E; Itokawa, N; Kanayama, K; Kanda, T; Kanzaki, H; Kato, N; Kiyono, S; Kobayashi, K; Kusakabe, Y; Maeda, T; Maruta, S; Maruyama, H; Mizumoto, H; Nakamoto, S; Nakamura, M; Obu, M; Ogasawara, S; Okabe, S; Ooka, Y; Saito, T; Seki, A; Sugiura, N; Suzuki, E; Tawada, A; Yasui, S; Yokoyama, M | 1 |
| Fujishiro, M; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Ito, T; Kuzuya, T; Yoshioka, N | 1 |
| Deng, M; Huang, F; Jia, C; Liang, H; Lin, N; Xiong, Z; Xu, J; Yao, Z | 1 |
| Amaddeo, G; Anders, M; Bhoori, S; Bruix, J; Crespo, G; Cristóbal, MR; Czauderna, C; Donato, MF; Giorgio, M; González-Diéguez, ML; Iavarone, M; Invernizzi, F; Lampertico, P; López, MF; Manini, MA; Mazzaferro, V; Piñero, F; Pinter, M; Regnault, H; Reig, M; Rodríguez, MJB; Sanduzzi-Zamparelli, M; Soteras, GA; Varela, M; Villadsen, GE; Weinmann, A; Wörns, MA | 1 |
| Cheng, SQ; Davidson, JC; Lau, WY; Lu, J; Madoff, DC; Qi, X; Teng, GJ; Zhang, XP; Zhong, BY | 1 |
| Fernández-Palanca, P; Fondevila, F; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C | 1 |
| Chin, DW; Law, CT; Lee, D; Ng, IO; Shen, J; Tsang, FH; Wei, L; Wong, CC; Wong, CL; Wong, CM; Zhang, A; Zhang, MS | 1 |
| Li, Q; Li, Y; Liang, R; Lin, Y; Liu, Z; Luo, M; Ye, J; Zhang, J; Zhang, Y | 1 |
| Bangaru, S; Marrero, JA; Singal, AG | 1 |
| Faivre, S; Finn, RS; Rimassa, L | 1 |
| Batuyong, E; Cheung, WY; Davies, J; Fung, AS; Knox, JJ; Ko, YJ; Lee-Ying, R; Meyers, DE; Samawi, H; Sim, HW; Tam, VC; Zaborska, V | 1 |
| Cadenas, M; Chapresto-Garzón, R; Gómez-Bravo, MA; Muntané, J; Navarro-Villarán, E; Negrete, M; Padillo, FJ; Rodríguez-Hernández, MA; Victor, VM | 1 |
| Fujisawa, M; Kanda, T; Kuroda, K; Masuzaki, R; Matsumoto, N; Matsuoka, S; Moriyama, M; Ogawa, M; Sasaki, R | 1 |
| Abou-Alfa, GK; Blanc, JF; Cheng, AL; Daniele, B; Guerra, I; Kelley, RK; Marteau, F; Mollon, P; Valcheva, V; Yau, T | 1 |
| Hinrichs, JB; Kirstein, MM; Manns, MP; Marwede, T; Pinter, M; Scheiner, B; Semmler, G; Vogel, A; Voigtländer, T; Wacker, F; Wolf, C | 1 |
| Cho, EJ; Jang, H; Kim, MA; Kim, SW; Kim, TY; Kim, YJ; Lee, CH; Lee, JH; Lee, KH; Lee, YB; Oh, H; Yoon, JH; Yu, SJ | 1 |
| Chien, CY; Hsu, MH; Hsu, SM; Liao, YJ; Suk, FM; Wang, YH | 1 |
| Han, S; Kim, DY | 1 |
| Chuma, M; Fukuda, H; Komiyama, S; Maeda, S; Moriya, S; Numata, K; Ogushi, K | 1 |
| Chang, SW; Chang, Y; Cho, SB; Hwang, SY; Jang, JY; Kim, JH; Lee, HW; Lee, MJ; Lee, YS; Seo, YS; Yim, HJ | 1 |
| Chung, WY; Dennison, AR; Huang, A; Yang, XR; Zhou, J | 1 |
| Card, PB; Knox, JJ; Lim, H; Liu, D; Meyers, BM; Ramjeesingh, R; Tam, VC | 1 |
| Bruix, J; da Fonseca, LG; Reig, M | 1 |
| Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G | 2 |
| Chou, CW; Huang, YK; Kuo, TT; Liu, JP; Sher, YP | 1 |
| Dáša, S; Igor, A; Ján, T; Jana, V | 1 |
| Astara, G; Bernardini, L; Casadei-Gardini, A; Cascinu, S; D'Amico, FE; Dadduzio, V; Fornaro, L; Lai, E; Lonardi, S; Masi, G; Pretta, A; Rimini, M; Rovesti, G; Scartozzi, M; Vivaldi, C; Zagonel, V | 1 |
| Dituri, F; Frusciante, M; Giannelli, G; Lupo, LG; Mancarella, S; Schmidt, TA; Scialpi, R; Villa, E | 1 |
| Ai, Y; Cao, Y; Ma, Y; Sun, Q; Wang, J; Wang, X; Yan, B; Zhang, Z | 1 |
| Bang, Y; Burgio, V; Casadei-Gardini, A; Cascinu, S; Frassineti, GL; Kim, HD; Lonardi, S; Massa, V; Park, SR; Rapposelli, IG; Rimini, M; Rizzato, MD; Ryoo, BY; Ryu, MH; Salani, F; Scartozzi, M; Valgiusti, M; Vivaldi, C; Yoo, C; Zagonel, V | 1 |
| Aikata, H; Amioka, K; Ando, Y; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Imamura, M; Kawaoka, T; Kikukawa, C; Kohno, H; Kosaka, Y; Kouno, H; Masaki, K; Mori, N; Morio, K; Murakami, E; Nakahara, T; Naruto, K; Ogawa, Y; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamauchi, M; Yoshikawa, Y | 1 |
| Bang, Y; Burgio, V; Casadei-Gardini, A; Cascinu, S; Catanese, S; Cucchetti, A; Kim, HD; Lonardi, S; Masi, G; Pellino, A; Rimassa, L; Rimini, M; Rizzato, MD; Ryoo, BY; Ryu, MH; Salani, F; Vivaldi, C; Yoo, C | 1 |
| Cui, X; Han, L; Li, Y; Liu, Y; Song, B; Sun, W; Wang, H; Zhang, Y; Zhou, W | 1 |
| Aikata, H; Aisaka, Y; Amioka, K; Ando, Y; Azakami, T; Chayama, K; Chihiro, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawaoka, T; Kodama, K; Kohno, H; Kosaka, Y; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Naeshiro, N; Nakahara, T; Naruto, K; Nonaka, M; Ogawa, Y; Suehiro, Y; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S; Yamauchi, M; Yoshikawa, Y | 1 |
| Cho, M; Hong, YM; Yoon, KT | 1 |
| Aikata, H; Ando, Y; Chayama, K; Fujii, Y; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kobayashi, T; Kosaka, Y; Kuroda, S; Miyata, Y; Morio, K; Murakami, E; Nakahara, T; Ohdan, H; Okada, M; Saeki, Y; Suehiro, Y; Takahashi, S; Tsuge, M; Uchikawa, S; Yamaoka, K; Yamauchi, M | 1 |
| Hanaoka, K; Kojima, H; Komatsu, T; Nagano, T; Ogihara, S; Okabe, T; Ueno, T; Urano, Y; Yanagi, K | 1 |
| Aballay Soteras, G; Amaddeo, G; Anders, M; Bhoori, S; Blanco Rodríguez, MJ; Bruix, J; Cesarini, L; Crespo, G; Czauderna, C; De Giorgio, M; Di Costanzo, G; Díaz-González, Á; Donato, MF; Fraile-López, M; González-Diéguez, ML; Iavarone, M; Invernizzi, F; Ivanics, T; Lampertico, P; Manini, MA; Mazza, S; Mazzaferro, V; Piñero, F; Pinter, M; Prince, R; Regnault, H; Reig, M; Romero Cristóbal, M; Sanduzzi-Zamparelli, M; Sapisochin, G; Scudeller, L; Tortora, R; Varela, M; Villadsen, GE; Weinmann, A; Wörns, MA; Yoon, PD; Yunquera, AF; Zavaglia, C | 1 |
| Chen, J; Wang, J; Xie, F | 1 |
| Dai, Z; Han, Q; Jiang, M; Lee, TH; Lin, J; Liu, H; Lu, KP; Peng, R; Wang, J; Wang, X; Zhang, B; Zheng, M | 1 |
| Fernández-Palanca, P; Fondevila, F; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Payo-Serafín, T; van Pelt, J; Verslype, C | 1 |
| Chang, WT; Chen, KY; Chen, SC; Cheng, TS; Chuang, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MH; Hsieh, MY; Hsu, CT; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Jang, TY; Ko, YM; Liang, PC; Lin, CC; Lin, YH; Lin, ZY; Tsai, YS; Wang, CW; Wei, YJ; Yeh, ML; Yu, ML | 1 |
| Altayar, O; Estfan, B; Falck-Ytter, Y; O'Shea, R; Shah, R; Su, GL; Sultan, S; Wenzell, C | 1 |
| Altayar, O; Chang, CY; Falck-Ytter, Y; Muir, AJ; Shah, R | 1 |
| Du, FH; Li, YL; Li, ZD; Wu, J; Wu, LW; Zeng, LH; Zhang, C; Zhang, MM | 1 |
| Abou-Alfa, GK; Cremolini, C; Crona, DJ; Etheridge, AS; Geyer, S; Hammond, K; Innocenti, F; Jacobson, SB; Marmorino, F; Peña, CE; Quintanilha, JCF; Racioppi, A; Rossini, D; Sanoff, HK | 1 |
| Fang, S; Li, X; Liu, G; Ma, Y; Yang, J; Yang, X; Zhao, B | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsu, PY; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Kang, T; Liao, D; Liu, W; Wang, X; Yu, X; Zeng, C; Zhang, R; Zhang, Y; Zhong, L | 1 |
| Baylan, SM; Erdal, E; Fırtına Karagonlar, Z; Guven, K; Karpat, O; Kıpçak, A; Sarıyar, E; Sezan, S | 1 |
| Cai, J; Fan, N; Guan, G; Huo, J; Li, Z; Qiu, W; Rao, W; Wang, S; Wu, L; Xin, Y; Zhu, Q | 1 |
| Filipič, M; Kološa, K; Novak, M; Štampar, M; Žegura, B | 1 |
| Arakawa, A; Iwata, S; Kawai, A; Kobayashi, E; Kumamoto, T; Maniwa, J; Nakajima, M; Ogawa, C; Shirakawa, N; Sugiyama, M; Tanimura, K; Tao, K; Watanabe, Y; Yoneda, A | 1 |
| Yang, S; Zeng, L; Zhou, Y | 1 |
| Alvarez-Ramirez, M; Díaz-Cedillo, F; Figueroa-Valverde, L; López-Gutierrez, T; López-Ramos, M; Mateu-Armad, MV; Rosas-Nexticapa, M | 1 |
| Chen, TL; Fang, CC; Liao, YJ; Suk, FM; Wu, CY | 1 |
37 review(s) available for sorafenib and regorafenib
| Article | Year |
|---|---|
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Development; Humans; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret | 2021 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
The preclinical development of regorafenib for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2014 |
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Topics: Animals; Antineoplastic Agents; Biological Transport; Glucuronides; Glucuronosyltransferase; Humans; Liver; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Tissue Distribution | 2015 |
Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.
Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Microenvironment | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2016 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib | 2017 |
Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2017 |
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Humans; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2017 |
Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Failure | 2017 |
Regorafenib for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2018 |
Regorafenib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug Approval; Humans; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2018 |
Review article: systemic treatment of hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2018 |
Molecular therapies and precision medicine for hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Precision Medicine; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2018 |
The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Forecasting; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Drug Substitution; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sunitinib; Treatment Outcome | 2019 |
Regorafenib: a promising treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2018 |
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Anilides; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Models, Animal; Molecular Targeted Therapy; Pharmacokinetics; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Treatment Outcome | 2019 |
Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Endovascular Procedures; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Liver Transplantation; Nivolumab; Patient Care Team; Phenylurea Compounds; Portal Vein; Pyridines; Quinolines; Radiotherapy, Adjuvant; Ramucirumab; Sorafenib; Stents; Venous Thrombosis | 2019 |
Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Gastrointestinal Neoplasms; Humans; Liver; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Microenvironment | 2019 |
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome | 2019 |
Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Liver Neoplasms; Neoplasm Staging; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Therapies, Investigational | 2020 |
Molecular therapies for HCC: Looking outside the box.
Topics: Algorithms; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Treatment Outcome | 2020 |
Targeted therapy for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2020 |
Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib; Survival Analysis; Vascular Endothelial Growth Factor A | 2021 |
Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma.
Topics: Anilides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinolines; Sorafenib | 2020 |
Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges.
Topics: Cachexia; Humans; Molecular Targeted Therapy; Multicenter Studies as Topic; Muscle, Skeletal; Neoplasms; Nutrition Assessment; Nutritional Status; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Randomized Controlled Trials as Topic; Recommended Dietary Allowances; Sorafenib; Sunitinib; Treatment Outcome | 2020 |
An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases.
Topics: ADAM Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Neoplasms; Neurodegenerative Diseases; Phenylurea Compounds; Pyridines; Retinal Diseases; Sorafenib; Tumor Microenvironment | 2020 |
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Neoplasm Metastasis; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib | 2021 |
AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib | 2022 |
KDR genetic predictor of toxicities induced by sorafenib and regorafenib.
Topics: Humans; Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Sorafenib | 2023 |
7 trial(s) available for sorafenib and regorafenib
| Article | Year |
|---|---|
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Serum Albumin; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Response Evaluation Criteria in Solid Tumors; Safety; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Computer Simulation; Cost-Benefit Analysis; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Liver Neoplasms; Markov Chains; Middle Aged; Monte Carlo Method; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome | 2018 |
85 other study(ies) available for sorafenib and regorafenib
| Article | Year |
|---|---|
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
Topics: Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoxide Hydrolases; Human Umbilical Vein Endothelial Cells; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyridines; Solubility; Sorafenib; Structure-Activity Relationship | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
Topics: Animals; Cell Proliferation; Drug Design; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Male; Mice; Patch-Clamp Techniques; Protein Kinase Inhibitors | 2016 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Picolinic Acids; Protein Kinase Inhibitors; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2019 |
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2013 |
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Off-Label Use; Panitumumab; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2013 |
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 Cells; Humans; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Thymoma; Thymus Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.
Topics: Autophagy; Cell Line; Cluster Analysis; Databases, Factual; Humans; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2014 |
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2014 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
Topics: Humans; Indazoles; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2015 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms | 2016 |
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Gene Knockout Techniques; HCT116 Cells; Heterografts; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transfection; Ubiquitin-Protein Ligases | 2017 |
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Movement; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2016 |
The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition.
Topics: Antineoplastic Agents; Ascorbic Acid; Cell Membrane; Cell Membrane Permeability; Cholesterol; Dithionite; Kinetics; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Phosphatidylcholines; Phosphatidylethanolamines; Pyridines; Sorafenib; Spin Labels; Staining and Labeling; Unilamellar Liposomes | 2016 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Depsipeptides; Disease Models, Animal; Humans; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |
Immune oncology in hepatocellular carcinoma-hype and hope.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
Topics: Chromatography, Liquid; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry | 2017 |
Sorafenib and Regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: Analysis of RESORCE and SHARP trials.
Topics: Carcinoma, Hepatocellular; Double-Blind Method; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Topics: Aged; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
The treatment path in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2017 |
Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Carcinoma, Hepatocellular; Depression, Chemical; Gene Expression; Hep G2 Cells; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Solubility; Sorafenib | 2018 |
Hepatocellular carcinoma in 2017: Two large steps forward, one small step back.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Drug Approval; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib | 2018 |
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2018 |
Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Topics: Animals; Annexin A3; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Matrix Metalloproteinases; Molecular Targeted Therapy; Multigene Family; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Tissue Inhibitor of Metalloproteinases | 2018 |
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Sorafenib | 2019 |
Impact of a Single Hydrogen Substitution by Fluorine on the Molecular Interaction and Miscibility between Sorafenib and Polymers.
Topics: Carbanilides; Fluorine; Gliclazide; Hydrogen; Phenylurea Compounds; Polymers; Povidone; Pyridines; Sorafenib | 2019 |
Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Wound Healing | 2019 |
RNAi-based small molecule repositioning reveals clinically approved urea-based kinase inhibitors as broadly active antivirals.
Topics: A549 Cells; Active Transport, Cell Nucleus; Antiviral Agents; Host-Pathogen Interactions; Humans; Influenza A virus; Influenza A Virus, H5N1 Subtype; Influenza B virus; Influenza, Human; Orthomyxoviridae; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; RNA Interference; RNA Viruses; RNA, Small Interfering; Sorafenib; Urea; Virus Replication | 2019 |
Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Molecular Imaging; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
A Single Hydrogen to Fluorine Substitution Reverses the Trend of Surface Composition Enrichment of Sorafenib Amorphous Solid Dispersion upon Moisture Exposure.
Topics: Fluorine; Humidity; Hydrogen; Phase Transition; Phenylurea Compounds; Polymers; Povidone; Pyridines; Solubility; Sorafenib; Steam; Surface Properties | 2019 |
Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
Topics: Amides; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Energy Metabolism; Glycogen; Glycogen Phosphorylase; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib | 2019 |
Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate | 2020 |
Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Hypersensitivity; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Sorafenib | 2019 |
Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression.
Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclic N-Oxides; Cyclin E; Drug Synergism; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Indolizines; Liver Neoplasms; Male; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Oncogene Proteins; Phenylurea Compounds; Piperidines; Prognosis; Pyridines; Pyridinium Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Sorafenib; Young Adult | 2019 |
Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Gene Knock-In Techniques; Gene Knockout Techniques; Humans; Liver Neoplasms; Phenylurea Compounds; Phosphoglycerate Dehydrogenase; Pyridines; Quinolines; Reactive Oxygen Species; Sorafenib | 2019 |
Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Canada; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Databases, Factual; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Patient Selection; Phenylurea Compounds; Pyridines; Ramucirumab; Randomized Controlled Trials as Topic; Sorafenib; Time Factors | 2020 |
Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells.
Topics: Adult; Anilides; Apoptosis; Cell Culture Techniques; Cell Differentiation; Cell Proliferation; Cell Respiration; Female; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Mitochondria; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; Spheroids, Cellular; Tumor Suppressor Protein p53 | 2020 |
Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Immunity, Innate; Liver Neoplasms; Neoplasm Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridines; Quinolines; Real-Time Polymerase Chain Reaction; Signal Transduction; Sorafenib; Toll-Like Receptors; Transcriptome | 2020 |
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Effectiveness Research; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Phenylurea Compounds; Progression-Free Survival; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2020 |
Sequential systemic treatment in patients with hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Nivolumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Ramucirumab; Sorafenib | 2020 |
Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Nivolumab; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2020 |
Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Barbiturates; Carcinoma, Hepatocellular; Caspase 7; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Phenylurea Compounds; Poly (ADP-Ribose) Polymerase-1; Pyridines; Sorafenib; Vimentin; Wound Healing; Xenograft Model Antitumor Assays | 2020 |
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Nivolumab; Phenylurea Compounds; Pyridines; Sorafenib | 2020 |
Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2020 |
Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Patient Acuity; Phenylurea Compounds; Progression-Free Survival; Pyridines; Republic of Korea; Retrospective Studies; Sex Factors; Sorafenib | 2021 |
Systemic treatment for hepatocellular carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Phenylurea Compounds; Pyridines; Ramucirumab; Sorafenib | 2020 |
Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib.
Topics: Antineoplastic Agents; Aspirin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Phenylurea Compounds; Proteoglycans; Pyridines; Sorafenib; Tumor Microenvironment | 2020 |
Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1.
Topics: Animals; Cell Line, Tumor; Cell Membrane; Concanavalin A; Cytochrome P-450 Enzyme System; Cytochrome-B(5) Reductase; Electron Transport; Fatty Acids, Unsaturated; Ferroptosis; HEK293 Cells; HeLa Cells; Humans; Hydrogen Peroxide; Lipid Peroxidation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; NADP; Oxygen; Phenylurea Compounds; Piperazines; Pyridines; Sorafenib | 2021 |
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Propensity Score; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Pyridines; Quinolines; Ramucirumab; Retrospective Studies; Sorafenib; Survival Rate | 2021 |
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Progression-Free Survival; Pyridines; Salvage Therapy; Sorafenib | 2021 |
siGCD: a web server to explore survival interaction of genes, cells and drugs in human cancers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, erbB-1; Genetic Heterogeneity; Glyburide; Humans; Lymphocytes, Tumor-Infiltrating; Neoplasms; Phenylurea Compounds; Precision Medicine; Pyridines; Software; Sorafenib; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2021 |
Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2021 |
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Prognosis; Progression-Free Survival; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Phenylurea Compounds; Pyridines; Sorafenib | 2021 |
Establishment of live-cell-based coupled assay system for identification of compounds to modulate metabolic activities of cells.
Topics: Amino Acids; Biological Assay; Cell Line, Tumor; Cell Survival; Cells; Fluorescent Dyes; Glycolysis; Humans; Metabolome; Phenylurea Compounds; Pyridines; Sorafenib | 2021 |
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2021 |
Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma.
Topics: Activating Transcription Factor 3; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Liver Neoplasms; Mice; Phenylurea Compounds; Pyridines; Receptors, Interleukin-6; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Hep G2 Cells; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Up-Regulation | 2021 |
Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Pyridines; Risk Factors; Salvage Therapy; Sorafenib; Survival Analysis; Taiwan | 2022 |
AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma.
Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Phenylurea Compounds; Pyridines; Quinolines; Ramucirumab; Retreatment; Sorafenib | 2022 |
DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions.
Topics: Dyrk Kinases; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Phenylurea Compounds; Protective Factors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2022 |
The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Spleen; Vascular Endothelial Growth Factor A | 2022 |
Advantage of clinical colchicine concentration to promote sorafenib or regorafenib anti-cancer effects on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colchicine; Humans; Liver Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2022 |
Targeting the Lysosomal Degradation of Rab22a-NeoF1 Fusion Protein for Osteosarcoma Lung Metastasis.
Topics: Humans; Lung Neoplasms; Lysosomes; Oncogene Proteins, Fusion; Osteosarcoma; Protein Kinases; rab GTP-Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases | 2023 |
EGFR and Lyn inhibition augments regorafenib induced cell death in sorafenib resistant 3D tumor spheroid model.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Sorafenib; Tumor Microenvironment | 2023 |
Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Adverse Toxic Effects of Tyrosine Kinase Inhibitors on Non-Target Zebrafish Liver (ZFL) Cells.
Topics: Animals; Antineoplastic Agents; Hepatocytes; Humans; Liver; Pyrimidines; Sorafenib; Tyrosine Kinase Inhibitors; Zebrafish | 2023 |
Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Everolimus; Female; Humans; Male; Neoplasm Recurrence, Local; Osteosarcoma; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tyrosine Kinase Inhibitors; Young Adult | 2023 |
Interaction of Some Amino-Nitrile Derivatives with Vascular Endothelial Growth Factor Receptor 1 (VEGFR1) Using a Theoretical Model.
Topics: Humans; Models, Theoretical; Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2023 |
β-HB treatment reverses sorafenib resistance by shifting glycolysis-lactate metabolism in HCC.
Topics: 3-Hydroxybutyric Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Lactates; Liver Neoplasms; Sorafenib | 2023 |